Price movement over the last 24 hours
Alcon AG vs United States Brent Oil Fund LP — how do they compare? Alcon AG trades at $66.79 (market cap $32.69B), while United States Brent Oil Fund LP trades at $43.39. The key difference: Alcon AG pays a 0.54% dividend while United States Brent Oil Fund LP pays none, and United States Brent Oil Fund LP is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | BNO | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Commodities - Energy |
52-Week High | $92.22 | $60.13 |
52-Week Low | $62.02 | $27.20 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
BNO trades at $39.94, up 0.68% on the day, amid a bearish technical backdrop with moving averages signaling caution and oscillators neutral. Recent news highlights oil price volatility driven by Middle East tensions and supply disruptions, though fundamental financial ratios are unavailable. The stock faces resistance near $40 with support at $39.
The outlook remains clouded by geopolitical risks and oil market volatility, with limited fundamental data. Upside depends on sustained oil price recovery, but downside risks from supply surges or demand weakness persist. Investors should weigh technical bearishness against external catalysts.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →BNO is a commodity ETF that tracks the daily price of Brent crude oil futures. It provides exposure to the international oil benchmark, which often trades at a premium to the U.S. WTI benchmark, and is primarily used for short-term trading due to roll costs.
Read more on BNO →